Affiliations 

  • 1 Department of Pharmacology and Pharmaceutical Chemistry, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, Selangor 42300 Malaysia
  • 2 Department of Pharmacology, Yashodeep Institute of Pharmacy, Sangram Nagar, Aurangabad, 431001 India
  • 3 Department of Pharmacology, Anurag Group of Institutions, Venkatapur, Ghatkesar, Hyderabad, Telangana 500088 India
  • 4 Unit of Pathology, International Medical School, Management & Science University, University Drive, Off Persiaran Olahraga, Section 13, Shah Alam, Selangor Darul Ehsan 40100 Malaysia
J Diabetes Metab Disord, 2022 Dec;21(2):1415-1426.
PMID: 36404813 DOI: 10.1007/s40200-022-01074-4

Abstract

OBJECTIVES: Glucose intolerance and insulin resistance are hallmarks of metabolic syndrome and lead to Alzheimer's disease (AD). The purpose of this study is to elucidate the neuroprotective effect of metformin through insulin regulation with cardiometabolic and neurotransmitter metabolic enzyme regulation in high-fat, high-sucrose diet and streptozotocin (HFHS-STZ)-induced rats.

METHODS: Male Wistar rats were treated with metformin (180 mg/kg and 360 mg/kg). STZ (35 mg/kg i.p.) injection was performed on the 14th day of 42 days of HFHS diet treatment. Brain neurotransmitter metabolic enzymes (acetylcholinesterase and monoamine oxidase) were determined along with sodium-potassium ATPase (Na+K+-ATPase). Plasma lipids and homeostasis model assessment of insulin resistance (HOMA-IR) was performed. Mean arterial blood pressure, heart rate and electrocardiogram (QT, QTc and RR intervals) were analysed with PowerLab.

RESULTS: Metformin treatment significantly (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.